Anti-EGFR antibodies and antibody drug conjugates
AssigneeAbbVie Inc.
InventorsEdward B. Reilly, Andrew C. Phillips, Lorenzo Benatuil, Chung-Ming Hsieh, Jennifer Perez
Life of this patent
Estimating the term…
Abstract
The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
Claims22
An anti-human epidermal growth factor receptor (anti-hEGFR) antibody comprising
- a heavy chain CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 12, a heavy chain CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 11, and a heavy chain CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 10;
- and
- a light chain CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 8, a light chain CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 7, and a light chain CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 6,
- wherein the antibody is an IgG isotype.
An antibody drug conjugate (ADC) comprising an anti-human epidermal growth factor receptor (anti-hEGFR) antibody conjugated to at least one auristatin, wherein the anti-hEGFR antibody is an IgG isotype and comprises
- a heavy chain variable region comprising a CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 12, a CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 11, and a CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 10;
- and
- a light chain variable region comprising a CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 8, a CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 7, and a CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 6.
An antibody drug conjugate (ADC) comprising an anti-EGFR IgG1 antibody covalently linked to maleimidocaproyl, valine-citrulline, p-aminobenzyloxycarbamyl-monomethylauristatin E (mc-vc-PABA-MMAE),
- wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:
- 9, and comprises a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:
- 5, and
- wherein 1 to 4 molecules of MMAE are linked to the antibody.
Dependencies are inferred from the claim text.